Scientific Reference
ARA-290 (Cibinetide)
Evidence profile: Human Phase 2 evidence
ARA-290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin (EPO), designed to selectively activate the Innate Repair Receptor (IRR) without stimulating erythropoiesis. By targeting the EPOR/β-common receptor complex, it delivers tissue-protective and anti-inflammatory effects without increasing red blood cell production. The compound has undergone multiple Phase 2 clinical trials and holds orphan drug designation for several conditions. Research has focused on its neuroprotective, anti-inflammatory, and regenerative properties, particularly in neuropathy, tissue injury, and autoimmune-related conditions.
Published Research
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Culver DA et al. · Investigative ophthalmology & visual science · 2017 · Clinical
PMID 28475703 — View on PubMedARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M et al. · Molecular medicine (Cambridge, Mass.) · 2015 · Clinical
PMID 25387363 — View on PubMedARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Dahan A et al. · Molecular medicine (Cambridge, Mass.) · 2013 · Clinical
PMID 24136731 — View on PubMedSafety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij L et al. · Molecular medicine (Cambridge, Mass.) · 2012 · Clinical
PMID 23168581 — View on PubMedManaging fatigue in sarcoidosis - A systematic review of the evidence
Atkins C et al. · Chronic respiratory disease · 2017 · Review
PMID 27507833 — View on PubMed